Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8926 |
High Similarity |
NPD1091 |
Approved |
0.822 |
Intermediate Similarity |
NPD2684 |
Approved |
0.8099 |
Intermediate Similarity |
NPD7843 |
Approved |
0.8088 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.8058 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.8031 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7983 |
Intermediate Similarity |
NPD290 |
Approved |
0.7955 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7903 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7868 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7868 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7868 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7842 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7795 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7778 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7778 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7755 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7734 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7734 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7714 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.771 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7704 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7681 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7681 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7655 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7634 |
Intermediate Similarity |
NPD3685 |
Discontinued |
0.7612 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7609 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7597 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7597 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7589 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7578 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7541 |
Intermediate Similarity |
NPD1358 |
Approved |
0.7537 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7483 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7481 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7481 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.744 |
Intermediate Similarity |
NPD228 |
Approved |
0.7429 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7426 |
Intermediate Similarity |
NPD3180 |
Approved |
0.7426 |
Intermediate Similarity |
NPD3179 |
Approved |
0.7407 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7381 |
Intermediate Similarity |
NPD821 |
Approved |
0.7381 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7372 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7338 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7338 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7338 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7323 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7319 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7317 |
Intermediate Similarity |
NPD3134 |
Approved |
0.7317 |
Intermediate Similarity |
NPD968 |
Approved |
0.7292 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7292 |
Intermediate Similarity |
NPD4535 |
Phase 3 |
0.728 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7278 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7278 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD291 |
Approved |
0.7273 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.726 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7234 |
Intermediate Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.7233 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7233 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7219 |
Intermediate Similarity |
NPD37 |
Approved |
0.7218 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7215 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7214 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7214 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7209 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7192 |
Intermediate Similarity |
NPD3122 |
Phase 3 |
0.719 |
Intermediate Similarity |
NPD4966 |
Approved |
0.719 |
Intermediate Similarity |
NPD4965 |
Approved |
0.719 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7188 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7183 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7174 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7165 |
Intermediate Similarity |
NPD969 |
Suspended |
0.7163 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD556 |
Approved |
0.7143 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD3847 |
Discontinued |
0.7132 |
Intermediate Similarity |
NPD1817 |
Approved |
0.7132 |
Intermediate Similarity |
NPD1820 |
Approved |
0.7132 |
Intermediate Similarity |
NPD1818 |
Approved |
0.7132 |
Intermediate Similarity |
NPD1819 |
Approved |
0.7123 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7122 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7111 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7111 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7111 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7111 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7111 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7109 |
Intermediate Similarity |
NPD1138 |
Approved |
0.7103 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7103 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7099 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7097 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7094 |
Intermediate Similarity |
NPD9365 |
Approved |
0.7086 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7083 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7083 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7083 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7075 |
Intermediate Similarity |
NPD5756 |
Phase 2 |
0.7059 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7059 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7059 |
Intermediate Similarity |
NPD2933 |
Approved |
0.7059 |
Intermediate Similarity |
NPD2934 |
Approved |
0.705 |
Intermediate Similarity |
NPD3166 |
Approved |
0.705 |
Intermediate Similarity |
NPD3164 |
Approved |
0.705 |
Intermediate Similarity |
NPD3167 |
Approved |
0.705 |
Intermediate Similarity |
NPD3165 |
Approved |
0.7045 |
Intermediate Similarity |
NPD1894 |
Discontinued |
0.7037 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7037 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7037 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7037 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.7037 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7031 |
Intermediate Similarity |
NPD1139 |
Approved |
0.7031 |
Intermediate Similarity |
NPD1137 |
Approved |
0.7029 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7021 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7021 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7021 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7021 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7015 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7007 |
Intermediate Similarity |
NPD6362 |
Approved |
0.7006 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD2860 |
Approved |
0.7 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD2859 |
Approved |
0.6985 |
Remote Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.698 |
Remote Similarity |
NPD3536 |
Discontinued |
0.6962 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6957 |
Remote Similarity |
NPD5647 |
Approved |
0.6957 |
Remote Similarity |
NPD3690 |
Phase 2 |
0.6957 |
Remote Similarity |
NPD3691 |
Phase 2 |
0.6957 |
Remote Similarity |
NPD6584 |
Phase 3 |
0.6957 |
Remote Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.695 |
Remote Similarity |
NPD1423 |
Approved |
0.6948 |
Remote Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.694 |
Remote Similarity |
NPD2668 |
Approved |
0.694 |
Remote Similarity |
NPD1778 |
Approved |
0.694 |
Remote Similarity |
NPD2667 |
Approved |
0.6934 |
Remote Similarity |
NPD7258 |
Clinical (unspecified phase) |
0.6933 |
Remote Similarity |
NPD7685 |
Pre-registration |
0.6929 |
Remote Similarity |
NPD4625 |
Phase 3 |
0.6923 |
Remote Similarity |
NPD1241 |
Discontinued |
0.6923 |
Remote Similarity |
NPD3054 |
Approved |
0.6923 |
Remote Similarity |
NPD3052 |
Approved |
0.6917 |
Remote Similarity |
NPD6581 |
Approved |
0.6917 |
Remote Similarity |
NPD6580 |
Approved |
0.6913 |
Remote Similarity |
NPD6799 |
Approved |
0.6913 |
Remote Similarity |
NPD7212 |
Phase 2 |
0.6913 |
Remote Similarity |
NPD7213 |
Phase 3 |
0.6897 |
Remote Similarity |
NPD2240 |
Approved |
0.6897 |
Remote Similarity |
NPD2239 |
Approved |
0.6894 |
Remote Similarity |
NPD3596 |
Phase 2 |
0.689 |
Remote Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.6884 |
Remote Similarity |
NPD1794 |
Approved |
0.6884 |
Remote Similarity |
NPD3094 |
Phase 2 |
0.6883 |
Remote Similarity |
NPD1934 |
Approved |
0.6871 |
Remote Similarity |
NPD3060 |
Approved |
0.6871 |
Remote Similarity |
NPD5062 |
Approved |
0.6871 |
Remote Similarity |
NPD5061 |
Approved |
0.6871 |
Remote Similarity |
NPD7007 |
Discovery |
0.6871 |
Remote Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.6866 |
Remote Similarity |
NPD6830 |
Clinical (unspecified phase) |
0.6866 |
Remote Similarity |
NPD5691 |
Approved |
0.6861 |
Remote Similarity |
NPD3676 |
Clinical (unspecified phase) |
0.6861 |
Remote Similarity |
NPD5327 |
Phase 3 |
0.6861 |
Remote Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.6855 |
Remote Similarity |
NPD940 |
Approved |
0.6855 |
Remote Similarity |
NPD846 |
Approved |
0.6849 |
Remote Similarity |
NPD6002 |
Phase 3 |
0.6849 |
Remote Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.6849 |
Remote Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.6849 |
Remote Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.6849 |
Remote Similarity |
NPD6005 |
Phase 3 |
0.6849 |
Remote Similarity |
NPD6004 |
Phase 3 |
0.6849 |
Remote Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.6846 |
Remote Similarity |
NPD5295 |
Discontinued |
0.6842 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6842 |
Remote Similarity |
NPD3687 |
Approved |
0.6842 |
Remote Similarity |
NPD3686 |
Approved |
0.6839 |
Remote Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.6838 |
Remote Similarity |
NPD1535 |
Discovery |
0.6835 |
Remote Similarity |
NPD558 |
Phase 2 |
0.6831 |
Remote Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.6829 |
Remote Similarity |
NPD3020 |
Approved |
0.6824 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6818 |
Remote Similarity |
NPD6387 |
Discontinued |
0.6818 |
Remote Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.6818 |
Remote Similarity |
NPD709 |
Approved |
0.6815 |
Remote Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.6815 |
Remote Similarity |
NPD4626 |
Approved |
0.6815
|
Remote Similarity |
NPD7075 |
Discontinued |